Northern Trust
GANX icon

Northern Trust’s Gain Therapeutics GANX Stock Holding History

Northern Trust’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Sell
97,013
-16,984
-15% -$31.3K ﹤0.01% 3939
2026
Q1 		$221K Buy
113,997
+11,996
+12% +$26.1K ﹤0.01% 3914
2025
Q4 		$328K Buy
102,001
+13,602
+15% +$36.3K ﹤0.01% 3801
2025
Q3 		$156K Sell
88,399
-11,771
-12% -$19.9K ﹤0.01% 4046
2025
Q2 		$180K Hold
100,170
– – ﹤0.01% 3970
2025
Q1 		$191K Buy
100,170
+15,584
+18% +$34.6K ﹤0.01% 3958
2024
Q4 		$183K Buy
84,586
+39,642
+88% +$79.6K ﹤0.01% 4018
2024
Q3 		$80K Hold
44,944
– – ﹤0.01% 4108
2024
Q2 		$57.5K Sell
44,944
-1,542
-3% -$4K ﹤0.01% 4188
2024
Q1 		$175K Buy
46,486
+2,973
+7% +$12.3K ﹤0.01% 3938
2023
Q4 		$142K Buy
43,513
+30,236
+228% +$84.1K ﹤0.01% 4019
2023
Q3 		$43.5K Hold
13,277
– – ﹤0.01% 4199
2023
Q2 		$59.5K Hold
13,277
– – ﹤0.01% 4175
2023
Q1 		$64K Buy
13,277
+731
+6% +$2.99K ﹤0.01% 4201
2022
Q4 		$39.3K Hold
12,546
– – ﹤0.01% 4341
2022
Q3 		$41K Buy
+12,546
New +$47.1K ﹤0.01% 4378

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust's GANX Position: Q2 2026 in Review

Northern Trust reduced its Gain Therapeutics (GANX) stake by 15% in Q2 2026, selling an estimated $31.3K and leaving 97,013 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #3939.

Northern Trust first reported a position in GANX in Q3 2022 and has held it in 16 quarters since. The position peaked at $328K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Northern Trust held 97,013 shares of Gain Therapeutics worth $197K as of Q2 2026.
  • Northern Trust sold 16,984 Gain Therapeutics shares in Q2 2026, an estimated $31.3K.
  • Gain Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3939 holding.
  • Northern Trust first reported a position in Gain Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Northern Trust's Gain Therapeutics position peaked at $328K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.